Ionis Pharmaceuticals, Inc.
NASDAQ:IONSBiotechnology
+$1.22 today
- Market cap
- $4.56B
- Beta
- 0.37
- P/E (TTM)
- -37.5
- EPS (TTM)
- -$1.98
Volume 3.23M
Average 1.83M
IONS Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Ionis Pharmaceuticals, Inc.NASDAQ: IONS
Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026
Cost of revenue grows, but more slowly than its trailing trend
Q3 FY2026 cost of revenue of $3.32M rose 42.1% year over year, behind the +44.2% change in trailing-twelve-month cost of revenue. Sequentially, it rose 21.3% from the prior quarter. Over 3 fiscal years it compounded at +4.3% a year.
Context
- Cost of revenue amounted to 1.7% of revenue in FY2025, up 0.1 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +42.1% toward the trailing-twelve-month pace of +44.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 16M USD
- Year-over-year change
- +42.7%
- 4-year CAGR
- +10.2%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 16M | +42.7% |
| FY2024 | 2024-12-31 | 11.22M | +22.8% |
| FY2023 | 2023-12-31 | 9.13M | -35.3% |
| FY2022 | 2022-12-31 | 14.12M | +30.2% |
| FY2021 | 2021-12-31 | 10.84M | — |
Cost of Revenue vs competitors
How IONS compares with its peers on the latest reported figures
- IONS's LTM Sep 2026 cost of revenue of $17.04M is the lowest of the 9 companies compared; the peer median is $500.8M.
- Its year-over-year change of +44.2% is the 6th highest of 9, against a peer median of +122.1%.
- Cost of revenue amounts to 1.8% of revenue for IONS, versus a peer median of 20.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $206.11B | +35566.9% | +13.6% | 20.1% | |
| LTM Jun 2026 | $3.21B | +17.0% | +8.3% | 32.3% | |
| LTM Jun 2026 | $974.34M | +141.9% | +58.9% | 20.3% | |
| LTM Mar 2026 | $821.4M | +102.3% | +84.7% | 37.6% | |
| LTM Jun 2026 | $180.19M | +250.5% | +17.1% | 17.9% | |
| LTM Mar 2026 | $167.7M | -26.7% | +28.1% | 253.7% | |
| LTM Mar 2026 | $109.99M | +25.2% | +56.7% | 16.4% | |
| LTM Jun 2026 | $47.45M | +428.8% | +101.9% | 6.7% | |
| LTM Sep 2026 | $17.04M | +44.2% | +4.3% | 1.8% | |
| Peer median (excluding IONS) | $500.8M | +122.1% | +42.4% | 20.2% | |
Competitors are the stored peer set for IONS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 810.46M | 587.37M | 787.65M | 705.14M | 944M |
| Cost of Revenue | 10.84M | 14.12M | 9.13M | 11.22M | 16M |
| Gross Profit | 799.61M | 573.25M | 778.51M | 693.92M | 928M |
| Gross Margin | 98.7% | 97.6% | 98.8% | 98.4% | 98.3% |
| Research & Development | 643M | 833M | 899.63M | 901.53M | 916M |
| Selling, General & Admin | 170.9M | 150.3M | 232.6M | 267.5M | 394M |
| Operating Expenses | 829.8M | 983.44M | 1.13B | 1.17B | 1.31B |
| Depreciation & Amortization | 19.56M | 22.11M | 22.5M | 21.99M | 22.69M |
| EBITDA | (5.19M) | (227.76M) | (235.87M) | (353.72M) | (284.31M) |
| EBITDA Margin | -0.6% | -38.8% | -29.9% | -50.2% | -30.1% |
| Operating Income | (30.19M) | (410.19M) | (353.73M) | (475.08M) | (382M) |
| Operating Margin | -3.7% | -69.8% | -44.9% | -67.4% | -40.5% |
| Interest Income | 10.04M | 25.33M | 89.04M | 107.02M | 97.77M |
| Interest Expense | 9.35M | 8.12M | 81.46M | 90.45M | 90.54M |
| Other Income / Expenses | 1.04M | 152.21M | 19.77M | 15.01M | 2M |
| Income Before Tax | (29.15M) | (257.99M) | (333.97M) | (460.07M) | (380M) |
| Pre-Tax Margin | -3.6% | -43.9% | -42.4% | -65.2% | -40.3% |
| Income Tax Expense | (551K) | 11.74M | 32.32M | (6.17M) | 1M |
| Net Income | (28.6M) | (269.72M) | (366.29M) | (453.9M) | (381M) |
| Net Margin | -3.5% | -45.9% | -46.5% | -64.4% | -40.4% |
| EPS (Basic) | (0.20) | (1.90) | (2.56) | (3.04) | (2.38) |
| EPS (Diluted) | (0.20) | (1.90) | (2.56) | (3.04) | (2.38) |
| Weighted Avg Shares | 141.02M | 141.85M | 143M | 149.51M | 160M |
| Weighted Avg Shares (Diluted) | 141.02M | 141.85M | 143.19M | 149.51M | 160M |
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
Intrinsic Alpha fair value
Locked
Current Price
$27.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.